UBS Group AG Decreases Position in GALAPAGOS NV/S (GLPG)

UBS Group AG reduced its stake in GALAPAGOS NV/S (NASDAQ:GLPG) by 59.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,202 shares of the biotechnology company’s stock after selling 1,795 shares during the period. UBS Group AG’s holdings in GALAPAGOS NV/S were worth $120,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its holdings in GALAPAGOS NV/S by 6.3% in the 1st quarter. Farallon Capital Management LLC now owns 308,260 shares of the biotechnology company’s stock worth $30,752,000 after acquiring an additional 18,260 shares during the period. Citadel Advisors LLC boosted its stake in shares of GALAPAGOS NV/S by 24.3% during the 1st quarter. Citadel Advisors LLC now owns 3,566 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 696 shares during the last quarter. Landscape Capital Management L.L.C. boosted its stake in shares of GALAPAGOS NV/S by 235.5% during the 1st quarter. Landscape Capital Management L.L.C. now owns 13,895 shares of the biotechnology company’s stock valued at $1,386,000 after buying an additional 9,754 shares during the last quarter. Employees Retirement System of Texas boosted its stake in shares of GALAPAGOS NV/S by 3.7% during the 1st quarter. Employees Retirement System of Texas now owns 56,000 shares of the biotechnology company’s stock valued at $5,587,000 after buying an additional 2,000 shares during the last quarter. Finally, Aperio Group LLC boosted its stake in shares of GALAPAGOS NV/S by 22.3% during the 1st quarter. Aperio Group LLC now owns 9,300 shares of the biotechnology company’s stock valued at $928,000 after buying an additional 1,697 shares during the last quarter. 17.38% of the stock is owned by institutional investors.

GALAPAGOS NV/S stock opened at $103.55 on Thursday. The company has a market cap of $5.55 billion, a PE ratio of -39.22 and a beta of 2.12. GALAPAGOS NV/S has a 52 week low of $84.13 and a 52 week high of $121.09.

GLPG has been the subject of several research analyst reports. BidaskClub upgraded GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 10th. Morgan Stanley increased their target price on GALAPAGOS NV/S from $126.00 to $127.00 and gave the company an “overweight” rating in a research note on Monday, August 6th. BTIG Research reiterated a “buy” rating and set a $118.00 target price on shares of GALAPAGOS NV/S in a research note on Sunday, April 29th. Cowen reiterated a “buy” rating on shares of GALAPAGOS NV/S in a research note on Thursday, May 31st. Finally, ValuEngine upgraded GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 28th. Four investment analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. GALAPAGOS NV/S has an average rating of “Buy” and an average price target of $109.00.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: Closed-End Mutual Funds

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply